nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—Lisinopril—systemic scleroderma	0.178	0.272	CbGbCtD
Linagliptin—ABCB1—Captopril—systemic scleroderma	0.133	0.203	CbGbCtD
Linagliptin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.105	0.16	CbGbCtD
Linagliptin—ABCB1—Prednisone—systemic scleroderma	0.0837	0.128	CbGbCtD
Linagliptin—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0627	0.0959	CbGbCtD
Linagliptin—CYP3A4—Prednisone—systemic scleroderma	0.0501	0.0767	CbGbCtD
Linagliptin—ABCB1—Methotrexate—systemic scleroderma	0.042	0.0642	CbGbCtD
Linagliptin—Hypoglycemic reaction—Lisinopril—systemic scleroderma	0.0159	0.0458	CcSEcCtD
Linagliptin—Diabetic—Captopril—systemic scleroderma	0.0123	0.0354	CcSEcCtD
Linagliptin—Diabetic—Lisinopril—systemic scleroderma	0.00868	0.0251	CcSEcCtD
Linagliptin—Bronchial hyperreactivity—Methotrexate—systemic scleroderma	0.00551	0.0159	CcSEcCtD
Linagliptin—Hyperlipidaemia—Leflunomide—systemic scleroderma	0.00468	0.0135	CcSEcCtD
Linagliptin—Hyperlipidaemia—Mycophenolic acid—systemic scleroderma	0.00446	0.0129	CcSEcCtD
Linagliptin—Diabetic—Methotrexate—systemic scleroderma	0.00431	0.0124	CcSEcCtD
Linagliptin—Hyperlipidaemia—Lisinopril—systemic scleroderma	0.00402	0.0116	CcSEcCtD
Linagliptin—Pancreatitis acute—Prednisone—systemic scleroderma	0.00373	0.0108	CcSEcCtD
Linagliptin—Hyperlipidaemia—Mycophenolate mofetil—systemic scleroderma	0.00352	0.0102	CcSEcCtD
Linagliptin—Diabetes mellitus—Captopril—systemic scleroderma	0.00342	0.00986	CcSEcCtD
Linagliptin—Nasopharyngitis—Mometasone—systemic scleroderma	0.00302	0.00873	CcSEcCtD
Linagliptin—Infestation NOS—Pentoxifylline—systemic scleroderma	0.00302	0.00872	CcSEcCtD
Linagliptin—Infestation—Pentoxifylline—systemic scleroderma	0.00302	0.00872	CcSEcCtD
Linagliptin—Hypertriglyceridaemia—Prednisone—systemic scleroderma	0.003	0.00865	CcSEcCtD
Linagliptin—Diabetes mellitus—Leflunomide—systemic scleroderma	0.00281	0.00812	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Mometasone—systemic scleroderma	0.00272	0.00784	CcSEcCtD
Linagliptin—Diabetes mellitus—Mycophenolic acid—systemic scleroderma	0.00269	0.00775	CcSEcCtD
Linagliptin—Blood triglycerides increased—Prednisone—systemic scleroderma	0.00263	0.00758	CcSEcCtD
Linagliptin—Urinary tract infection—Mometasone—systemic scleroderma	0.00253	0.00731	CcSEcCtD
Linagliptin—Pancreatitis—Captopril—systemic scleroderma	0.00252	0.00726	CcSEcCtD
Linagliptin—Immune system disorder—Pentoxifylline—systemic scleroderma	0.00245	0.00707	CcSEcCtD
Linagliptin—Diabetes mellitus—Lisinopril—systemic scleroderma	0.00242	0.00698	CcSEcCtD
Linagliptin—Hypoglycaemia—Mycophenolic acid—systemic scleroderma	0.00239	0.00691	CcSEcCtD
Linagliptin—Pain in extremity—Mycophenolic acid—systemic scleroderma	0.00234	0.00674	CcSEcCtD
Linagliptin—Back pain—Pentoxifylline—systemic scleroderma	0.00228	0.00659	CcSEcCtD
Linagliptin—Pancreatitis—Azathioprine—systemic scleroderma	0.0022	0.00634	CcSEcCtD
Linagliptin—Angioedema—Pentoxifylline—systemic scleroderma	0.00216	0.00622	CcSEcCtD
Linagliptin—Hypoglycaemia—Lisinopril—systemic scleroderma	0.00216	0.00622	CcSEcCtD
Linagliptin—Diabetes mellitus—Mycophenolate mofetil—systemic scleroderma	0.00212	0.00612	CcSEcCtD
Linagliptin—Immune system disorder—Mometasone—systemic scleroderma	0.00211	0.0061	CcSEcCtD
Linagliptin—Mediastinal disorder—Mometasone—systemic scleroderma	0.00211	0.00609	CcSEcCtD
Linagliptin—Pain in extremity—Lisinopril—systemic scleroderma	0.0021	0.00607	CcSEcCtD
Linagliptin—Nasopharyngitis—Mycophenolic acid—systemic scleroderma	0.00209	0.00603	CcSEcCtD
Linagliptin—Pancreatitis—Leflunomide—systemic scleroderma	0.00207	0.00599	CcSEcCtD
Linagliptin—Myalgia—Pentoxifylline—systemic scleroderma	0.00201	0.0058	CcSEcCtD
Linagliptin—Infestation NOS—Azathioprine—systemic scleroderma	0.002	0.00577	CcSEcCtD
Linagliptin—Infestation—Azathioprine—systemic scleroderma	0.002	0.00577	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.002	0.00576	CcSEcCtD
Linagliptin—Pancreatitis—Mycophenolic acid—systemic scleroderma	0.00198	0.00571	CcSEcCtD
Linagliptin—Back pain—Mometasone—systemic scleroderma	0.00197	0.00569	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Leflunomide—systemic scleroderma	0.00197	0.00568	CcSEcCtD
Linagliptin—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00193	0.00556	CcSEcCtD
Linagliptin—Infection—Pentoxifylline—systemic scleroderma	0.00191	0.00552	CcSEcCtD
Linagliptin—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00189	0.00545	CcSEcCtD
Linagliptin—Infestation NOS—Leflunomide—systemic scleroderma	0.00189	0.00545	CcSEcCtD
Linagliptin—Infestation—Leflunomide—systemic scleroderma	0.00189	0.00545	CcSEcCtD
Linagliptin—Nasopharyngitis—Lisinopril—systemic scleroderma	0.00188	0.00543	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Mycophenolic acid—systemic scleroderma	0.00188	0.00541	CcSEcCtD
Linagliptin—Skin disorder—Pentoxifylline—systemic scleroderma	0.00187	0.0054	CcSEcCtD
Linagliptin—Angioedema—Mometasone—systemic scleroderma	0.00186	0.00537	CcSEcCtD
Linagliptin—Weight increased—Mycophenolic acid—systemic scleroderma	0.00184	0.0053	CcSEcCtD
Linagliptin—Urinary tract infection—Leflunomide—systemic scleroderma	0.00183	0.00529	CcSEcCtD
Linagliptin—Infestation NOS—Mycophenolic acid—systemic scleroderma	0.0018	0.00519	CcSEcCtD
Linagliptin—Infestation—Mycophenolic acid—systemic scleroderma	0.0018	0.00519	CcSEcCtD
Linagliptin—Pancreatitis—Lisinopril—systemic scleroderma	0.00178	0.00514	CcSEcCtD
Linagliptin—Cough—Mometasone—systemic scleroderma	0.00178	0.00513	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Pentoxifylline—systemic scleroderma	0.00176	0.00507	CcSEcCtD
Linagliptin—Urinary tract infection—Mycophenolic acid—systemic scleroderma	0.00175	0.00505	CcSEcCtD
Linagliptin—Arthralgia—Mometasone—systemic scleroderma	0.00173	0.005	CcSEcCtD
Linagliptin—Myalgia—Mometasone—systemic scleroderma	0.00173	0.005	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.00169	0.00488	CcSEcCtD
Linagliptin—Anaphylactic shock—Mometasone—systemic scleroderma	0.00166	0.0048	CcSEcCtD
Linagliptin—Weight increased—Lisinopril—systemic scleroderma	0.00165	0.00478	CcSEcCtD
Linagliptin—Infection—Mometasone—systemic scleroderma	0.00165	0.00477	CcSEcCtD
Linagliptin—Constipation—Pentoxifylline—systemic scleroderma	0.00165	0.00475	CcSEcCtD
Linagliptin—Skin exfoliation—Prednisone—systemic scleroderma	0.00164	0.00474	CcSEcCtD
Linagliptin—Angioedema—Captopril—systemic scleroderma	0.00163	0.00472	CcSEcCtD
Linagliptin—Immune system disorder—Azathioprine—systemic scleroderma	0.00162	0.00468	CcSEcCtD
Linagliptin—Mediastinal disorder—Azathioprine—systemic scleroderma	0.00162	0.00466	CcSEcCtD
Linagliptin—Urinary tract infection—Lisinopril—systemic scleroderma	0.00158	0.00455	CcSEcCtD
Linagliptin—Pancreatitis—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00451	CcSEcCtD
Linagliptin—Cough—Captopril—systemic scleroderma	0.00156	0.00451	CcSEcCtD
Linagliptin—Urticaria—Pentoxifylline—systemic scleroderma	0.00153	0.00442	CcSEcCtD
Linagliptin—Immune system disorder—Leflunomide—systemic scleroderma	0.00153	0.00442	CcSEcCtD
Linagliptin—Mediastinal disorder—Leflunomide—systemic scleroderma	0.00153	0.00441	CcSEcCtD
Linagliptin—Arthralgia—Captopril—systemic scleroderma	0.00152	0.0044	CcSEcCtD
Linagliptin—Myalgia—Captopril—systemic scleroderma	0.00152	0.0044	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.00151	0.00437	CcSEcCtD
Linagliptin—Malnutrition—Leflunomide—systemic scleroderma	0.00147	0.00426	CcSEcCtD
Linagliptin—Anaphylactic shock—Captopril—systemic scleroderma	0.00146	0.00421	CcSEcCtD
Linagliptin—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.00146	0.0042	CcSEcCtD
Linagliptin—Weight increased—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00418	CcSEcCtD
Linagliptin—Diabetes mellitus—Prednisone—systemic scleroderma	0.00144	0.00415	CcSEcCtD
Linagliptin—Back pain—Leflunomide—systemic scleroderma	0.00143	0.00412	CcSEcCtD
Linagliptin—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.00142	0.0041	CcSEcCtD
Linagliptin—Infestation—Mycophenolate mofetil—systemic scleroderma	0.00142	0.0041	CcSEcCtD
Linagliptin—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00142	0.0041	CcSEcCtD
Linagliptin—Malnutrition—Mycophenolic acid—systemic scleroderma	0.00141	0.00406	CcSEcCtD
Linagliptin—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00398	CcSEcCtD
Linagliptin—Skin exfoliation—Methotrexate—systemic scleroderma	0.00137	0.00396	CcSEcCtD
Linagliptin—Back pain—Mycophenolic acid—systemic scleroderma	0.00136	0.00393	CcSEcCtD
Linagliptin—Angioedema—Leflunomide—systemic scleroderma	0.00135	0.00389	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00133	0.00384	CcSEcCtD
Linagliptin—Myalgia—Azathioprine—systemic scleroderma	0.00133	0.00384	CcSEcCtD
Linagliptin—Arthralgia—Azathioprine—systemic scleroderma	0.00133	0.00384	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00132	0.00381	CcSEcCtD
Linagliptin—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00132	0.0038	CcSEcCtD
Linagliptin—Mediastinal disorder—Lisinopril—systemic scleroderma	0.00131	0.00379	CcSEcCtD
Linagliptin—Cough—Leflunomide—systemic scleroderma	0.00129	0.00371	CcSEcCtD
Linagliptin—Malnutrition—Lisinopril—systemic scleroderma	0.00127	0.00366	CcSEcCtD
Linagliptin—Infection—Azathioprine—systemic scleroderma	0.00127	0.00365	CcSEcCtD
Linagliptin—Myalgia—Leflunomide—systemic scleroderma	0.00126	0.00362	CcSEcCtD
Linagliptin—Arthralgia—Leflunomide—systemic scleroderma	0.00126	0.00362	CcSEcCtD
Linagliptin—Constipation—Captopril—systemic scleroderma	0.00125	0.0036	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00125	0.0036	CcSEcCtD
Linagliptin—Skin disorder—Azathioprine—systemic scleroderma	0.00124	0.00357	CcSEcCtD
Linagliptin—Cough—Mycophenolic acid—systemic scleroderma	0.00123	0.00354	CcSEcCtD
Linagliptin—Back pain—Lisinopril—systemic scleroderma	0.00123	0.00354	CcSEcCtD
Linagliptin—Rash—Pentoxifylline—systemic scleroderma	0.00121	0.00351	CcSEcCtD
Linagliptin—Dermatitis—Pentoxifylline—systemic scleroderma	0.00121	0.0035	CcSEcCtD
Linagliptin—Headache—Pentoxifylline—systemic scleroderma	0.00121	0.00348	CcSEcCtD
Linagliptin—Anaphylactic shock—Leflunomide—systemic scleroderma	0.0012	0.00347	CcSEcCtD
Linagliptin—Diabetes mellitus—Methotrexate—systemic scleroderma	0.0012	0.00346	CcSEcCtD
Linagliptin—Arthralgia—Mycophenolic acid—systemic scleroderma	0.0012	0.00346	CcSEcCtD
Linagliptin—Myalgia—Mycophenolic acid—systemic scleroderma	0.0012	0.00346	CcSEcCtD
Linagliptin—Infection—Leflunomide—systemic scleroderma	0.0012	0.00345	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00119	0.00343	CcSEcCtD
Linagliptin—Skin disorder—Leflunomide—systemic scleroderma	0.00117	0.00337	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00116	0.00335	CcSEcCtD
Linagliptin—Angioedema—Lisinopril—systemic scleroderma	0.00116	0.00334	CcSEcCtD
Linagliptin—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00332	CcSEcCtD
Linagliptin—Infection—Mycophenolic acid—systemic scleroderma	0.00114	0.00329	CcSEcCtD
Linagliptin—Diarrhoea—Mometasone—systemic scleroderma	0.00114	0.00328	CcSEcCtD
Linagliptin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00112	0.00322	CcSEcCtD
Linagliptin—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00111	0.0032	CcSEcCtD
Linagliptin—Cough—Lisinopril—systemic scleroderma	0.00111	0.00319	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.0011	0.00317	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.0011	0.00316	CcSEcCtD
Linagliptin—Arthralgia—Lisinopril—systemic scleroderma	0.00108	0.00311	CcSEcCtD
Linagliptin—Myalgia—Lisinopril—systemic scleroderma	0.00108	0.00311	CcSEcCtD
Linagliptin—Back pain—Mycophenolate mofetil—systemic scleroderma	0.00107	0.0031	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00107	0.00309	CcSEcCtD
Linagliptin—Pancreatitis—Prednisone—systemic scleroderma	0.00106	0.00306	CcSEcCtD
Linagliptin—Rash—Mometasone—systemic scleroderma	0.00105	0.00302	CcSEcCtD
Linagliptin—Dermatitis—Mometasone—systemic scleroderma	0.00105	0.00302	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00105	0.00302	CcSEcCtD
Linagliptin—Headache—Mometasone—systemic scleroderma	0.00104	0.00301	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00104	0.003	CcSEcCtD
Linagliptin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00103	0.00298	CcSEcCtD
Linagliptin—Constipation—Leflunomide—systemic scleroderma	0.00103	0.00297	CcSEcCtD
Linagliptin—Infection—Lisinopril—systemic scleroderma	0.00103	0.00296	CcSEcCtD
Linagliptin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00293	CcSEcCtD
Linagliptin—Skin disorder—Lisinopril—systemic scleroderma	0.001	0.0029	CcSEcCtD
Linagliptin—Diarrhoea—Captopril—systemic scleroderma	0.000999	0.00288	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000991	0.00286	CcSEcCtD
Linagliptin—Weight increased—Prednisone—systemic scleroderma	0.000983	0.00284	CcSEcCtD
Linagliptin—Constipation—Mycophenolic acid—systemic scleroderma	0.000982	0.00283	CcSEcCtD
Linagliptin—Cough—Mycophenolate mofetil—systemic scleroderma	0.000969	0.0028	CcSEcCtD
Linagliptin—Urticaria—Leflunomide—systemic scleroderma	0.000956	0.00276	CcSEcCtD
Linagliptin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000945	0.00273	CcSEcCtD
Linagliptin—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000945	0.00273	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000942	0.00272	CcSEcCtD
Linagliptin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000939	0.00271	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000939	0.00271	CcSEcCtD
Linagliptin—Rash—Captopril—systemic scleroderma	0.000921	0.00266	CcSEcCtD
Linagliptin—Dermatitis—Captopril—systemic scleroderma	0.00092	0.00265	CcSEcCtD
Linagliptin—Headache—Captopril—systemic scleroderma	0.000915	0.00264	CcSEcCtD
Linagliptin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000906	0.00261	CcSEcCtD
Linagliptin—Infection—Mycophenolate mofetil—systemic scleroderma	0.0009	0.0026	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000893	0.00258	CcSEcCtD
Linagliptin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000887	0.00256	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—systemic scleroderma	0.000885	0.00255	CcSEcCtD
Linagliptin—Constipation—Lisinopril—systemic scleroderma	0.000884	0.00255	CcSEcCtD
Linagliptin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00088	0.00254	CcSEcCtD
Linagliptin—Diarrhoea—Azathioprine—systemic scleroderma	0.000872	0.00252	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000839	0.00242	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000825	0.00238	CcSEcCtD
Linagliptin—Diarrhoea—Leflunomide—systemic scleroderma	0.000823	0.00238	CcSEcCtD
Linagliptin—Urticaria—Lisinopril—systemic scleroderma	0.000821	0.00237	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—systemic scleroderma	0.000805	0.00232	CcSEcCtD
Linagliptin—Infestation—Methotrexate—systemic scleroderma	0.000805	0.00232	CcSEcCtD
Linagliptin—Rash—Azathioprine—systemic scleroderma	0.000803	0.00232	CcSEcCtD
Linagliptin—Dermatitis—Azathioprine—systemic scleroderma	0.000803	0.00232	CcSEcCtD
Linagliptin—Headache—Azathioprine—systemic scleroderma	0.000798	0.0023	CcSEcCtD
Linagliptin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000785	0.00227	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000782	0.00226	CcSEcCtD
Linagliptin—Immune system disorder—Prednisone—systemic scleroderma	0.000781	0.00225	CcSEcCtD
Linagliptin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000775	0.00224	CcSEcCtD
Linagliptin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000762	0.0022	CcSEcCtD
Linagliptin—Rash—Leflunomide—systemic scleroderma	0.000759	0.00219	CcSEcCtD
Linagliptin—Dermatitis—Leflunomide—systemic scleroderma	0.000758	0.00219	CcSEcCtD
Linagliptin—Headache—Leflunomide—systemic scleroderma	0.000754	0.00218	CcSEcCtD
Linagliptin—Malnutrition—Prednisone—systemic scleroderma	0.000752	0.00217	CcSEcCtD
Linagliptin—Rash—Mycophenolic acid—systemic scleroderma	0.000724	0.00209	CcSEcCtD
Linagliptin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000723	0.00209	CcSEcCtD
Linagliptin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00072	0.00208	CcSEcCtD
Linagliptin—Headache—Mycophenolic acid—systemic scleroderma	0.000719	0.00208	CcSEcCtD
Linagliptin—Diarrhoea—Lisinopril—systemic scleroderma	0.000707	0.00204	CcSEcCtD
Linagliptin—Angioedema—Prednisone—systemic scleroderma	0.000688	0.00198	CcSEcCtD
Linagliptin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000667	0.00193	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—systemic scleroderma	0.000652	0.00188	CcSEcCtD
Linagliptin—Rash—Lisinopril—systemic scleroderma	0.000652	0.00188	CcSEcCtD
Linagliptin—Dermatitis—Lisinopril—systemic scleroderma	0.000651	0.00188	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000651	0.00188	CcSEcCtD
Linagliptin—Headache—Lisinopril—systemic scleroderma	0.000648	0.00187	CcSEcCtD
Linagliptin—Arthralgia—Prednisone—systemic scleroderma	0.000641	0.00185	CcSEcCtD
Linagliptin—Myalgia—Prednisone—systemic scleroderma	0.000641	0.00185	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000636	0.00184	CcSEcCtD
Linagliptin—Malnutrition—Methotrexate—systemic scleroderma	0.000629	0.00181	CcSEcCtD
Linagliptin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00062	0.00179	CcSEcCtD
Linagliptin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000614	0.00177	CcSEcCtD
Linagliptin—Infection—Prednisone—systemic scleroderma	0.00061	0.00176	CcSEcCtD
Linagliptin—Back pain—Methotrexate—systemic scleroderma	0.000608	0.00176	CcSEcCtD
Linagliptin—Skin disorder—Prednisone—systemic scleroderma	0.000596	0.00172	CcSEcCtD
Linagliptin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000571	0.00165	CcSEcCtD
Linagliptin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000571	0.00165	CcSEcCtD
Linagliptin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000568	0.00164	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000559	0.00161	CcSEcCtD
Linagliptin—Cough—Methotrexate—systemic scleroderma	0.000549	0.00158	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—systemic scleroderma	0.000535	0.00155	CcSEcCtD
Linagliptin—Arthralgia—Methotrexate—systemic scleroderma	0.000535	0.00155	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000532	0.00153	CcSEcCtD
Linagliptin—Constipation—Prednisone—systemic scleroderma	0.000525	0.00152	CcSEcCtD
Linagliptin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000513	0.00148	CcSEcCtD
Linagliptin—Infection—Methotrexate—systemic scleroderma	0.00051	0.00147	CcSEcCtD
Linagliptin—Skin disorder—Methotrexate—systemic scleroderma	0.000498	0.00144	CcSEcCtD
Linagliptin—Urticaria—Prednisone—systemic scleroderma	0.000488	0.00141	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000468	0.00135	CcSEcCtD
Linagliptin—Hypersensitivity—Prednisone—systemic scleroderma	0.000452	0.00131	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000443	0.00128	CcSEcCtD
Linagliptin—Diarrhoea—Prednisone—systemic scleroderma	0.00042	0.00121	CcSEcCtD
Linagliptin—Urticaria—Methotrexate—systemic scleroderma	0.000408	0.00118	CcSEcCtD
Linagliptin—Rash—Prednisone—systemic scleroderma	0.000387	0.00112	CcSEcCtD
Linagliptin—Dermatitis—Prednisone—systemic scleroderma	0.000387	0.00112	CcSEcCtD
Linagliptin—Headache—Prednisone—systemic scleroderma	0.000385	0.00111	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—systemic scleroderma	0.000378	0.00109	CcSEcCtD
Linagliptin—Diarrhoea—Methotrexate—systemic scleroderma	0.000351	0.00101	CcSEcCtD
Linagliptin—Rash—Methotrexate—systemic scleroderma	0.000324	0.000934	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—systemic scleroderma	0.000323	0.000933	CcSEcCtD
Linagliptin—Headache—Methotrexate—systemic scleroderma	0.000322	0.000928	CcSEcCtD
